GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-02-23| Asia-Pacific

Takeda Taps Code Biotherapeutics to Develop Non-Viral Gene Therapies in $2 Billion Biobucks Deal

by Joy Lin
Share To

Takeda is dangling $2 billion on the line to access Code Biotherapeutics’ 3DNA non-viral gene delivery platform. The Japanese drug giant aims to use the platform to develop up to four rare disease programs. 

The first program will target the liver, while the two companies will also conduct additional studies for central nervous system-directed rare disease programs. 

Upon closing of the deal, Code Bio will receive “double-digit million dollars” in upfront, near-term milestone and research funding payments. The biotech could also receive up to $2 billion if milestones for all four programs are met, as well as royalties on product sales. 

Takeda and Code Bio will jointly research and select candidates, which Takeda has the option to license for further development and commercialization.  

 

The Advantages of Non-Viral Gene Delivery

 

Many high-profile gene therapies use viral vectors, such as AAVs, to deliver their genetic payload. While this method sees relatively high uptake by cells, it has the potential to stimulate unwanted immune responses. Off-target effects are another risk, as the gene may insert itself in a random location in the genome, possibly causing gene mutations that may lead to cancer. 

More than a few AAV gene therapies have landed in hot water over the potential risks. In recent years the FDA had slapped clinical holds on AAV gene therapies developed by Astellas, Biomarin, Homology Medicines, bluebird bio, and UniQure. Some of these holds have yet to be resolved. 

Code Bio is one of the emerging companies that are working on non-viral gene delivery. Its vector consists of strands of synthetic DNA, linked together to form a scaffold. 

The company believes its platform can overcome the limitations of most gene delivery methods, and says that its vector allows specific cell targeting, is able to deliver large genetic payloads, and can be re-dosed, unlike AAV therapies. 

Preclinical studies indicate that the platform is specific and effective at delivering genes without causing off-target effects or observable safety concerns, the company said. 

Besides the Takeda deal, Code Bio has a program for Duchenne muscular dystrophy in the discovery pipeline. Another program takes aim at type 1 diabetes. 

Related Article: BIO CEO: Overcoming the Obstacles in Developing Gene Therapies

 

Companies Developing Non-Viral Gene Therapies

 

Philadelphia-based Code Bio launched last April to a $10 million seed funding round which saw participation from the venture arm of Takeda. It faces competition from a number of companies already working on non-viral gene therapies. 

Last October, Takeda inked a deal worth $3.6 billion with Poseida to develop up to eight non-viral gene therapies. 

And Generation Bio clinched $230 million in a Nasdaq IPO in 2020 to fund its lead hemophilia gene therapy, which uses close-ended DNA strands and liquid nanoparticle delivery. 

Related Article: Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
FDA Approves Kebilidi: First Brain-Delivered Gene Therapy for Rare AADC Disease
2024-11-15
R&D
The Latest in Alzheimer’s Research: Restoring Cognitive Function with Nanotech, Gene Therapy, and Enhanced Brain Gamma Oscillations
2024-08-16
Revolutionizing Treatment: ASGCT’s Clinical Trials Spotlight on Immunotherapy, Cancer Vaccines, and Auditory Diseases
2024-05-09
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top